Literature DB >> 8786964

Extensive absorption of 2',3'-dideoxyinosine by intratracheal administration in rats.

X Gao1, M G Wientjes, J L Au.   

Abstract

PURPOSE: To evaluate the intratracheal route of administration as an alternative to oral administration for 2',3'-dideoxyinosine (ddI).
METHODS: A ddI dose (40 mg/kg/300 microliters or 6.5 mg/kg/50 microliters) was instilled into the trachea in female Fisher rats and an intravenous tracer dose (9 micrograms/kg) of 3H-ddI was administered concomitantly to determine the drug clearance. Plasma concentrations were analyzed for the rate and extent of absorption.
RESULTS: ddI was rapidly absorbed from the lungs, with a bioavailability of 63% at 40 mg/kg and 101% at 6.5 mg/kg. By comparison, our previous data showed an oral bioavailability of about 15% (Pharm Res., 9:822, 1992). The distribution of a dye solution instilled intratracheally showed that a fraction of the 300 microliters dose spilled over to the gastrointestinal tract, where the entire 50 microliters dose was retained in the lungs. The different distribution of the two doses volumes likely contributed to the different bioavailability, with a fraction of the higher dose/volume degraded in the gastrointestinal tract after the spillover. Absorption of ddI from the airspace of the lung was biexponential, suggesting two absorption processes.
CONCLUSIONS: These data indicate significantly higher and less variable bioavailability of ddI by the intratracheal route of delivery compared to the oral route. Furthermore, the complete bioavailability at the lower dose/volume indicates no significant pulmonary first pass elimination for ddI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8786964     DOI: 10.1023/a:1016283604540

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  Efficiency of different criteria for selecting pharmacokinetic multiexponential equations.

Authors:  B P Imbimbo; P Martinelli; M Rocchetti; G Ferrari; G Bassotti; E Imbimbo
Journal:  Biopharm Drug Dispos       Date:  1991-03       Impact factor: 1.627

2.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

3.  Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in rats.

Authors:  S L Bramer; J L Au; M G Wientjes
Journal:  J Pharmacol Exp Ther       Date:  1993-05       Impact factor: 4.030

4.  Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers.

Authors:  S Kobayashi; S Kondo; K Juni
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

5.  Short term disposition of soluble vs. insoluble forms of cadmium in rat lung after intratracheal administration: an autoradiographic assessment.

Authors:  M Aihara; R P Sharma; J L Shupe
Journal:  Toxicology       Date:  1985-08       Impact factor: 4.221

6.  Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

Authors:  S L Bramer; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

7.  High-performance liquid chromatographic analysis of 2',3'-dideoxyinosine in biological samples.

Authors:  M G Wientjes; J L Au
Journal:  J Chromatogr       Date:  1991-02-15

8.  Nonlinear disposition of intravenous 2',3'-dideoxyinosine in rats.

Authors:  M G Wientjes; E Mukherji; J L Au
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

9.  Penetration kinetics of 2',3'-dideoxyinosine in dermis is described by the distributed model.

Authors:  E Gupta; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

10.  Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Authors:  C A Knupp; W C Shyu; R Dolin; F T Valentine; C McLaren; R R Martin; K A Pittman; R H Barbhaiya
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.